This page has beta status

BMBS COST Action BM1304
Applications of MR imaging and spectroscopy techniques in neuromuscular disease: collaboration on outcome measures and pattern recognition for diagnostics and therapy development

Neuromuscular diseases (NMD) form a large group of individually rare diseases that are present in all populations and affect people of all ages. Many of them result in chronic disability, posing a significant healthcare burden for society. Diagnosis and therapy development for NMD has rapidly expanded in recent years and there is an urgent need to develop objective, non-invasive outcome measures to monitor disease progression and treatment effect. The use of novel magnetic resonance imaging and spectroscopy techniques (MRI and MRS) applied to NMD is showing increasing promise in this regard, but progress has been hindered by the rarity of the conditions and lack of options for pooling data from different groups. This COST Action will overcome the main hurdles to rollout of MR techniques by sharing expertise and data, validating protocols across platforms and exploring the potential of MRI and MRS as a helpful diagnostic tool and a quantitative outcome measure in NMD clinical trials. The objectives of standardizing applications of MRI and MRS in NMD, training of early stage researchers and the development of an online atlas of neuromuscular imaging will enhance knowledge of scientists and healthcare professionals and ultimately benefit patients with NMD.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Volker STRAUB (UK)

Vice Chair of the Action:

Dr Pierre CARLIER (FR)

Science officer of the Action:


Administrative officer of the Action:

Ms Jeannette NCHUNG ORU


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF


Action website:

* content provided by e-COST.
Data is synchronised once per night.


Last updated: 28 May 2013 top of page